Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2008
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi). The company has no approved products and relies on strategic alliances, government contracts, and equity financing to fund operations. Key programs include ALN-RSV01 (Phase II for RSV), ALN-VSP (liver cancer), and ALN-PCS (hypercholesterolemia).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|---|
| Net Revenues | $23,833 | $46,025 | $16,350 |
| Operating Expenses | $36,664 | $62,813 | $55,297 |
| Loss from Operations | $(12,831) | $(16,788) | $(38,947) |
| Net Loss | $(12,760) | $(13,999) | $(34,336) |
| Net Loss Per Share (Basic/Diluted) | $(0.31) | $(0.34) | $(0.92) |
| Cash and Cash Equivalents (End of Period) | $247,536 (as of June 30, 2008) | ||
| Marketable Securities (End of Period) | |||
| Total Liquidity (Cash + Securities) | $538,323 (as of June 30, 2008) | ||
| Deferred Revenue (Total) | $349,674 (as of June 30, 2008) | ||
| Notes Payable (Total) | $4,906 (Principal outstanding) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 161% for the six months ended June 30, 2008, compared to the same period in 2007. This was driven primarily by the recognition of revenue from the Roche alliance (effective August 2007) and the new Takeda alliance (signed May 2008).
- Operating Loss Improvement: The operating loss narrowed significantly from $(38.9) million in the prior six-month period to $(16.8) million, despite higher operating expenses, due to the substantial revenue increase.
- Operating Expenses: Total operating expenses increased 14% year-over-year for the six-month period. Research and Development (R&D) expenses rose 10%, largely due to a $5.0 million license fee payment to Isis related to the Takeda deal and a $2.1 million charge for a Tekmira investment premium.
- Cash Flow: Net cash provided by operating activities turned positive at $86.4 million for the six months ended June 30, 2008, compared to a use of $19.4 million in the prior year. This shift was primarily due to an $86.4 million increase in deferred revenue from new alliance payments.
Guidance, Outlook, and Material Events
Strategic Alliances
- Takeda Alliance (May 2008): Entered into a license and collaboration agreement. Takeda paid $100 million upfront (received June 2008) with an additional $50 million in near-term technology transfer milestones. Revenue is recognized on a straight-line basis over seven years.
- Kyowa Hakko Alliance (June 2008): Granted exclusive license for ALN-RSV01 in Japan and Asia. Received $15 million upfront. Revenue recognition is deferred until the performance period can be reasonably estimated.
- Roche Alliance: Continues to be a primary revenue source, with $278.2 million deferred revenue recognized over five years.
Outlook and Liquidity
Management believes existing resources, combined with expected cash from current alliances (Roche, Takeda, Novartis), are sufficient to fund operations for at least the next several years. The company expects to continue incurring net losses as it advances clinical trials and expands its pipeline.
Risks and Contingencies
- Regulatory Risk: No RNAi therapeutics have received regulatory approval. Success depends on demonstrating safety and efficacy in clinical trials.
- Patent Litigation: The company faces opposition proceedings regarding key RNAi patents (e.g., Kreutzer-Limmer, Glover) in the European Patent Office and other jurisdictions.
- Joint Venture: Alnylam holds a 49% interest in Regulus Therapeutics LLC (microRNA focus). The company recognized an equity loss of $3.2 million for the six months ended June 30, 2008.
Investor Verification Checklist
- Revenue Recognition Policy: Verify the straight-line recognition periods for the Takeda (7 years) and Roche (5 years) agreements and the deferral status of the Kyowa Hakko revenue.
- License Fee Obligations: Confirm the $5.0 million payment to Isis Pharmaceuticals triggered by the Takeda deal and its impact on R&D expenses.
- Cash Burn Rate: Assess the sustainability of the current cash position ($538 million) against projected R&D spend and the timeline for potential product commercialization.
- Patent Status: Review the status of opposition proceedings against the Glover and Kreutzer-Limmer patents, which are critical to the company's IP portfolio.
- Joint Venture Exposure: Evaluate the financial health of Regulus Therapeutics and the potential for additional capital calls or equity losses.